Director/PDMR Shareholding | RNS | Ticker

/News/RNS

Director/PDMR Shareholding

RNS Announcement

RNS Number : 6287M

GlaxoSmithKline PLC

14 October 2016

GlaxoSmithKline plc (the 'Company')

Transaction notification

Details of PDMR/person closely associated with them ('PCA')

Name

Sir Andrew Witty

Position/status

Chief Executive Officer

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	38

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Mr R G Connor

Position/status

President, Global Manufacturing & Supply

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	47

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Mr S Dingemans

Position/status

Chief Financial Officer

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)

Volume(s)

£17.0491

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Mr N Hirons

Position/status

SVP, Global Ethics & Compliance

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	5

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Mr S A Hussain

Position/status

President, Global Pharmaceuticals

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	9

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Mr D S Redfern

Position/status

Chief Strategy Officer

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	53

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Ms C Thomas

Position/status

SVP, Human Resources

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	53

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Mr P C Thomson

Position/status

SVP, Communications & Government Affairs

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	28

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Dr P J T Vallance

Position/status

President, Pharmaceuticals R&D

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	31

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Ms E Walmsley

Position/status

CEO Designate

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	10

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Mrs V A Whyte

Position/status

Company Secretary

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and

volume(s)

Price(s)	Volume(s)
£17.0491	37

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHQZLFFQBFLFBE

RNS metadata

Title: Director/PDMR Shareholding
Time: 18:27:42
Date: 14 Oct 2016
Category: Director/PDMR dealings
ID: 6287M